上海宣泰医药科技股份有限公司 一、募集资金基本情况 证券代码：688247 证券简称：宣泰医药 公告编号：2023-031 （一）实际募集资金金额、资金到位情况 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]1383 号），公司获准向社会公开发 行人民币普通股（A）股 45,340,000.00 股，发行价格为 9.37 元/股，募集资金总 额为人民币 42,483.58 万元，扣除与发行相关的费用（不含增值税）人民币 4,761.77 万元，实际募集资金净额为人民币 37,721.81 万元。 2022 年 8 月 22 日，上述募集资金已经全部到账并存放于公司募集资金专户 管理。公司对募集资金采取了专户存储制度，设立了相关募集资金专项账户。募 集资金到账后，公司与保荐机构、存放募集资金的银行签署了募集资金专户存储 监管协议。上述资金到位情况经上会会计师事务所（特殊普通合伙）审验，并出 具上会师报字(2022)第 9072 号《验资报告》。 （二）2023 年半年度募集资金使用情况及结余情况 2023 年半年度募集资金存放与使用情况的专项 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2023-033 视 频 和 线 上 文 字 互 动 平 台 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （http://roadshow.sseinfo.com/） 投资者可于 2023 年 9 月 6 日(星期三)16:00 前通过邮件、电话、传真等形式 将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普遍关 注的问题进行回答。 上海宣泰医药科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 30 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 半年度经营成果、财务状况、发展理念，公司参与了由上交所主办的 2023 半年度 制药及生物制品行业集体业绩说明会，此次活动将采用视频和线上文字互动的方式 举行，投资者可登录上海证券交易所上证路演中心（http://roadshow.sseinfo.com/） 参与线上互动交流。 一、 说明会类型 上海宣泰医药科技股份有限公司 关于参加 2023 半年度制药及生物制品行业集体业绩说 明会的公告 本公司董事会及全体董事保证本公告内容不存在 ...

上海宣泰医药科技股份有限公司 第二届监事会第二次会议决议公告 证券代码：688247 证券简称：宣泰医药 公告编号：2023-034 2.审议通过《关于 2023 年半年度募集资金存放与使用情况的专项报告的议 案》 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海宣泰医药科技股份有限公司（以下简称"公司"）第二届监事会第二次 会议于 2023 年 8 月 28 日以现场方式召开。本次会议通知于 2023 年 8 月 22 日 以邮件形式发送。本次会议应出席监事 3 人，实际出席监事 3 人，会议由监事会 主席王燕清女士主持。会议的召集和召开程序符合《中华人民共和国公司法》等 有关法律法规及《公司章程》的规定。 二、监事会会议审议情况 1.审议通过《关于 2023 年半年度报告及摘要的议案》 监事会认为：公司 2023 年半年度报告的编制和审议程序符合法律、法规、 《公司章程》和公司内部管理制度的各项规定；公司 2023 年半年度报告的内容 与格式符合中国证券监督管理委员会和上海证券交易所的各项规 ...

海通证券股份有限公司 目拟投入募集资金金额及增加实施主体、实施地点的公告》（公告编号：2022-001）、 《上海宣泰医药科技股份有限公司关于部分募投项目变更的公告》（公告编号： 2023-011），公司首次公开发行股票募集资金净额将用于以下项目： | 序号 | 项目名称 | 投资总额（万元） | 拟使用募集资金 （万元） | | --- | --- | --- | --- | | 1 | 制剂生产综合楼及 相关配套设施项目 | 32,000.00 | 545.57 | | 2 | 复杂制剂车间及相 关配套设施项目 | 9,605.00 | 9,176.24 | | 3 | 高端仿制药和改良 型新药研发项目 | 23,830.16 | 19,610.00 | | 4 | 补充流动资金 | 8,390.00 | 8,390.00 | | | 合计 | 73,825.16 | 37,721.81 | 截至 2023 年 6 月 30 日，公司募集资金余额 25,145.94 万元，其中账户活期 金额 10,145.94 万元，未到期大额存单及结构性存款 15,000.00 万元。 三、本次使用部分闲置募集资金进行 ...

Financial Performance - The total revenue for the year 2022 was CNY 247.56 million, a decrease of 21.53% year-on-year[3]. - The operating profit for 2022 was CNY 99.13 million, down 18.28% compared to the previous year[3]. - The total profit for the year was CNY 97.48 million, reflecting a decline of 34.59% year-on-year[3]. - The net profit attributable to shareholders was CNY 92.94 million, a decrease of 31.11% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was CNY 74.20 million, down 15.17% year-on-year[3]. - The company's operating revenue for 2022 was ¥247,562,432.66, a decrease of 21.53% compared to 2021[21]. - The net profit attributable to shareholders decreased by 31.11% to ¥92,941,482.96, primarily due to intensified competition in the U.S. market[24]. - The net cash flow from operating activities fell by 49.80% to ¥73,183,720.97, attributed to reduced income from equity participation and government subsidies[24]. - Basic earnings per share decreased by 33.33% to ¥0.22, reflecting the decline in net profit attributable to shareholders[22]. - The weighted average return on equity decreased to 10.59%, down 10.63 percentage points from 2021[22]. - The company's total revenue for the reporting period was 247.56 million, a year-on-year decrease of 21.53%[33]. - The net profit attributable to the parent company was 92.94 million, down 31.11% year-on-year, while the net profit excluding non-recurring gains and losses was 74.20 million, a decrease of 15.17%[33]. Competition and Market Conditions - The company faced intensified competition in the U.S. market for its product Posaconazole enteric-coated tablets, leading to a significant decline in revenue from profit-sharing[3]. - The company has not experienced any major adverse changes in its core business or competitive capabilities, and its ability to continue operations is not at significant risk[3]. - The company has disclosed various risks it may face in its production and operation processes in the report[3]. - The company reported a significant decline in equity participation income, which fell by 80.17% to ¥120,341,000[24]. - The company is exposed to risks from potential changes in tax policies that could increase income tax expenses[104]. Research and Development - The R&D investment as a percentage of operating revenue was 30.71%, a decrease of 2.14 percentage points from the previous year[22]. - The company achieved technology transfer revenue of ¥6,485.95 million from self-developed projects during the reporting period[24]. - The company has established three core R&D technology platforms, enhancing its competitive edge in the high-end generic drug market[89]. - The total R&D investment for the year was approximately ¥76.02 million, a decrease of 26.64% compared to the previous year, with R&D investment accounting for 30.71% of operating revenue[82]. - The company has submitted multiple drug applications, including for Posaconazole enteric-coated tablets and Bupropion hydrochloride sustained-release tablets, which have been approved in China and the US[85]. - The company has established advanced drug formulation technology platforms, including solubility enhancement and controlled-release drug formulation[153]. Product Development and Approvals - The company received approvals for several products, including ursodeoxycholic acid capsules and paroxetine enteric-coated sustained-release tablets, enhancing its product portfolio[36]. - The company has obtained ANDA approvals for five generic drugs, including the first generic of Posaconazole delayed-release tablets approved by the FDA[45]. - The company has launched new drug products such as Orebatinib tablets and has received domestic approvals for several first-generic drugs[46]. - The company is in the process of developing new products, including Olaparib Tablets and Mesalazine Enteric-Coated Tablets, with submissions made in 2022[158]. Financial Management and Investments - The company plans to distribute a cash dividend of CNY 0.62 per share, totaling CNY 28.11 million, which represents 30.24% of the net profit attributable to shareholders[5]. - The cash flow from financing activities increased significantly due to the issuance of new shares in August 2022, resulting in a net cash inflow of CNY 375.65 million[114]. - The company invested 200 million yuan in Innodarbo and purchased property for a new R&D center, leading to increased cash outflow[139]. - The company reported a total of CNY 1.99 billion in financial derivatives purchased during the reporting period[174]. Market Expansion and Strategy - The company is focusing on market expansion and new product development, with a commitment to invest in innovative technologies[196]. - The management team has outlined a future outlook that includes a projected revenue growth of 20% for the next fiscal year[196]. - The company is actively pursuing mergers and acquisitions to enhance its market position and expand its product offerings[196]. - A new strategic initiative has been launched to improve operational efficiency, targeting a 15% reduction in costs over the next two years[196]. - The company plans to increase its R&D budget by 25% to accelerate the development of new technologies[196]. Governance and Compliance - The company strictly adheres to relevant laws and regulations, ensuring the governance structure and internal control systems are continuously improved[184]. - The board of directors and supervisory board members possess the necessary knowledge and skills to fulfill their responsibilities effectively[185]. - The company maintains independence from its controlling shareholder in terms of business, personnel, assets, and finance, ensuring no interference in decision-making[185]. - The company actively engages with investors through roadshows and performance briefings, effectively communicating its investment value[185].

Financial Performance - The company's operating revenue for Q1 2023 was ¥42,418,265.20, a decrease of 32.86% compared to the same period last year[5] - The net profit attributable to shareholders was ¥7,716,721.48, down 61.92% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥5,374,407.65, reflecting a decline of 72.57%[5] - Total revenue for Q1 2023 was ¥42,418,265.20, a decrease of 32.8% compared to ¥63,179,209.56 in Q1 2022[20] - Operating profit for Q1 2023 was ¥7,823,729.78, down 66.7% from ¥23,452,801.43 in Q1 2022[21] - Net profit for Q1 2023 was ¥7,716,721.48, a decline of 61.9% compared to ¥20,263,118.79 in Q1 2022[21] - Total comprehensive income for Q1 2023 was ¥7,692,372.68, a decrease of 62.0% from ¥20,255,766.17 in Q1 2022[22] - Basic earnings per share were ¥0.02, down 65.73% year-on-year[6] - Basic earnings per share for Q1 2023 was ¥0.02, down from ¥0.05 in Q1 2022[22] Cash Flow and Liquidity - The net cash flow from operating activities increased by 97.80% to ¥18,585,769.41, primarily due to the collection of receivables[6] - Cash flow from operating activities for Q1 2023 was ¥18,585,769.41, an increase of 97.5% compared to ¥9,396,461.26 in Q1 2022[25] - The net cash flow from financing activities was -$99,558.00, a decrease from -$190,392.00 in the previous period, indicating improved cash management[26] - The net increase in cash and cash equivalents was -$313,354,291.53, compared to -$222,102,490.77 in the prior year, reflecting a significant cash outflow[26] - The beginning balance of cash and cash equivalents was $763,148,303.68, up from $511,651,941.84 year-over-year, showing a strong starting position[26] - The ending balance of cash and cash equivalents was $449,794,012.15, a decrease from $289,549,451.07 in the previous period, indicating a decline in liquidity[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,328,874,706.25, a slight decrease of 0.26% from the end of the previous year[6] - Total assets decreased slightly to ¥1,328,874,706.25 from ¥1,332,333,946.07, a decrease of about 0.3%[19] - Total liabilities decreased to ¥143,898,463.87 from ¥155,050,076.37, a reduction of approximately 7.2%[18] - The company’s equity attributable to shareholders increased to ¥1,184,976,242.38 from ¥1,177,283,869.70, an increase of about 0.7%[19] - The company reported a total current assets of ¥950,917,454.71, slightly down from ¥953,710,436.33[17] - The company’s non-current assets totaled ¥377,957,251.54, a minor decrease from ¥378,623,509.74[17] Research and Development - Research and development expenses totaled ¥10,885,029.09, a decrease of 41.50% compared to the previous year[6] - Research and development expenses decreased to ¥10,885,029.09 in Q1 2023 from ¥18,605,791.17 in Q1 2022, representing a reduction of 41.7%[20] - The company did not achieve revenue recognition for R&D technology transfer during the reporting period, resulting in a 100% year-on-year decline in related income[8] Market and Competition - The company faced increased competition in the U.S. market, leading to a 23% year-on-year decline in sales share[8] - The company’s product Posaconazole enteric-coated tablets and sustained-release bupropion hydrochloride tablets were included in the National Basic Medical Insurance Drug List, effective March 1, 2023, which is expected to enhance market accessibility[14] - The company’s Ursodeoxycholic acid capsules were selected in the eighth batch of national centralized procurement, effective July 2023, which is anticipated to boost sales growth[14] Inventory and Receivables - Accounts receivable decreased to ¥33,388,777.90 from ¥64,302,436.57, a reduction of about 48.0%[16] - Inventory increased to ¥34,621,655.40 from ¥29,376,771.68, reflecting an increase of approximately 17.3%[17] - The company reported a credit impairment loss of ¥1,619,789.58 in Q1 2023, compared to a loss of ¥606,233.66 in Q1 2022[21] Return on Equity - The return on equity (ROE) was 0.65%, a decrease of 2.18 percentage points compared to the previous year[6]

2022 年第三季度报告 证券代码：688247 证券简称：宣泰医药 上海宣泰医药科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 注:"本报告期"指本季度初至本季度末 3 个月期间，下同。 (二)非经常性损益项目和金额 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上 年同期增减变 | 年初至报告期末 | 年初至报告期末 比上年同期增减 | | --- | --- | --- | --- | --- | | | | 动幅度(%) | | 变动幅度(%) | | 营业收入 | 59,050,376.49 | ...